期刊
EXPERT OPINION ON DRUG SAFETY
卷 14, 期 2, 页码 207-218出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2015.987122
关键词
cancer risk; GLP-1 receptor agonists; incretin-based therapy; side effects
资金
- Astra Zeneca
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Ely Lilly
- Merck Sharp Dohme
- Novartis
- Novo Nordisk
- Sanofi- Aventis
- Takeda
Introduction: Glucagon-like peptide 1 receptor (GLP-1Rx) agonists might elicit unwelcome side effects and concerns have recently been raised about their safety. Areas covered: Available evidence about safety, tolerability and potential adverse events relative to GLP-1Rx agonists presently used. We searched the MEDLINE database using the terms: 'GLP-1 receptor agonists', 'Incretin therapy side effects', 'exenatide', 'liraglutide', 'exenatide long-acting release', ' lixisenatide'. Articles were selected on the basis of the study design and importance, in the light of authors' clinical experience and personal judgment. The main safety concern about GLP-1Rx agonists use is the possible association with increased risk of pancreatitis and/or tumors. This concern stems mainly from limited observations in animal models not confirmed in similar studies. Furthermore, clinical studies reporting association between GLP-1Rx agonist use and pancreatitis/cancer are marred by several biases and both clinical trials and post-marketing analyses failed to demonstrate a significant association. Expert opinion: As stated by both FDA and EMA, the safety concerns emerged so far about GLP-1RX agonists should not affect present prescribing habits. Thus, although a strict data monitoring must be encouraged, they should not prevent access to the benefits of an innovative treatment, such as GLP-1Rx agonists use, to a large diabetic population still confronted with unmet needs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据